CDx are a form of personalised, stratified, and precision medicine, and they herald a new era of treatment in which a patient’s treatment will become increasingly individualised.

Listed below are the key regulatory trends impacting the CDx theme, as identified by GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Impact of clinical guidelines and CDx

Clinical guidelines play an important role in CDx as they represent the current state of scientific knowledge, offering judgments that give providers guidance on the range of acceptable clinical pathways for numerous cancers. Clinical trials remain the gold standard for evidence in guideline development. However, for practical and cost reasons, these trials are typically focused on assessing efficacy. Guideline developers are typically responsible for assessing both the safety and benefit-risk balance of a treatment in addition to efficacy.

These guidelines can have an effect on the type of products that do well in the market. Professional societies such as the College of American Pathologists (CAP) and the US Centers for Disease Control and Prevention (CDC) have laid the early groundwork for regulations and guidelines that will likely grow more specific and rigorous in the future.

For example, guidelines by CAP, International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) state that Sanger sequencing is not considered suitable for clinical use for epidermal growth factor receptor (EGFR) mutations. This is likely to affect the market growth for this diagnostic technique.

This is an edited extract from the Companion Diagnostics – Thematic Research report produced by GlobalData Thematic Research.